ReviewMolecular biology reports2026
Terpenes and terpenoids modulating TRPV channels in diabetes: role in fibrosis and inflammatory signaling.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transient receptor potential vanilloid (TRPV) channels are non-selective cation channels that mediate thermosensation, nociception, osmotic balance, and metabolic regulation. In diabetes, altered TRPV channel expression and decreased calcium influx key pathways modulates, include NF-κB, AMPK, and TGF-β, promoting extracellular matrix accumulation and fibrotic remodelling. The limited availability of pathway specific interventions highlights TRPV channels as potential therapeutic target in diabetes. Recently, natural phytoconstituents have shown to exhibit TRPV channel modulating properties. Studies also highlights the potential of terpenes and terpenoids to inhibit NF-κB mediated inflammation, and activate AMPK-promoted metabolic homeostasis, mitigating diabetes-associated tissue damage. Preclinical studies have explored major terpenoids such as d-limonene, p-cymene and carvacrol in diabetic models. These compounds have been reported to improve glucose tolerance and alter the blood glucose levels via different molecular mechanisms. Clinically, there are limited evidences reporting terpenoids in the metabolic syndrome and TRPV modulation. Example, Astaxanthin, a tetraterpenoid has multiple human trials in type 2 diabetes, reducing diabetic biomarkers like SIRT1, HbA1c, and fasting glucose. This review summarizes current evidence on terpenes and terpenoids in diabetes with their reported and proposed interactions with TRPV1, TRPV4 with particular emphasis on their potential links to oxidative stress, NF-κB-mediated inflammation, TGF-β-associated fibrosis, and metabolic signaling. By distinguishing experimentally supported TRPV modulation with mechanistic associations and which require further validation, this review provides an integrated framework for understanding potential contribution of terpenoid-TRPV interactions to diabetes progression and its inflammatory and fibrotic complications, while highlighting key gaps for future experimental and translational investigation.
Indexed as
Identifiers
42859291What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.